8 October 2024 UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101.
Denmark’s Bavarian Nordic, which has won a number of significant contracts for its smallpox vaccine Imvanex that has also shown efficacy against monkeypox, an infectious disease that has been spreading strongly, is now taking advantage of its windfall to expand its travel vaccines portfolio. 15 February 2023
February 15, 2023
US biotech major Biogen today reported financials for 2022, showing that fourth quarter revenues were $2,544 million, a decline of 7% but beating consensus forecasts of $2.45 billion. 15 February 2023
The Secretary of the US Department of Health and Human Services (HHS) has selected three new models for testing by the Centers for Medicare & Medicaid Services’ (CMS) Innovation Center to help lower the high cost of medicines in the USA. 15 February 2023
Indian generics major Zydus Lifesciences has received tentative approval from the US Food and Drug Administration (FDA) to market canagliflozin tablets, 100mg and 300mg. 15 February 2023
With its recently granted expanded approval by the US Food and Drug Administration (FDA) for Gilead Sciences’ Trodelvy (sacituzumab govitecan-hziy) - for patients with HR-positive/HER2-negative metastatic breast cancer who have received hormonal therapy and at least two additional therapies – the drug is expected to become a standard of care for these breast cancer patients, who have had limited treatment options. 15 February 2023
US rare diseases specialist Soligenix closed 19% lower after Tuesday’s trading following news of a setback with its lead drug candidate. 15 February 2023
Canadian precision meds company Fusion Pharmaceuticals has announced the acquisition from Texas, USA-based RadioMedix, of the investigational new drug application (IND) for an ongoing Phase II clinical trial. 15 February 2023
Shares of US biotech Gritstone bio were up 2.23% t $2.67 pre-marker as the company, announced that it has entered into a clinical trial agreement with the National Cancer Institute (NCI), an institute of the USA’s National Institutes of Health. 15 February 2023
Florida, USA-based Axogen, which is developing and marketing innovative solutions for peripheral nerve injuries, has announced the appointment of Jens Schroeder Kemp to the newly created role of chief marketing officer. 15 February 2023
UK pharma major GSK is discontinuing its collaboration with Vir Biotechnology on vaccines against COVID-19, with Vir continuing to discover, develop and advance next-generation solutions for COVID-19 and other potential coronavirus outbreaks, independently or with other partners. 14 February 2023
German life sciences and technology company Merck KGaA has announced findings of a new analysis of long-term follow-up data from the Phase III JAVELIN Bladder 100 trial. 14 February 2023
The range medicines available in Russian pharmacies is steadily declining, which is mainly due to tough economic environment in the country, caused by Western sanctions and the existing problems with logistics, reports The Pharma Letter’s local correspondent. 14 February 2023
Last week’s US Food and Drug Administration (FDA) clinical hold on genetic medicines company 4D Molecular Therapeutics Fabry disease (FD) gene therapy program (4D-310) could benefit fellow US drugmaker Sangamo Therapeutics. 14 February 2023
Sorrento Therapeutics, a US company focused on acquiring, developing and commercializing non-opioid pain management products, has issued a statement alongside its majority-owned subsidiary Scilex Holding Company. 14 February 2023
Shares of US regenerative medicines firm Frequency Therapeutics plummeted more than 80% to $0.75 yesterday, after it announced it is terminating programs in sensorineural hearing loss (SNHL) because FX-322 failed to meet the goal of a study in people with acquired SNHL, and is slashing its workforce. 14 February 2023
Following the announcement that Sanofi’s global head of R&D John Reed is leaving the French drugmaker, his destination has been revealed as the US healthcare giant Johnson & Johnson. 14 February 2023
China and USA-based Harbour BioMed saw its shares rise more than 7% to HK$3.17, after it announced an exclusive license agreement with US firm Cullinan Oncology for the development and commercial rights on HBM7008 (CLN-418) in the USA. 14 February 2023
Sage Therapeutics’ share price fell 11% to $6 in pre-market activity on Tuesday, after it announced disappointing top-line results from LIGHTWAVE. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
The UK has launched a new Regulatory Innovation Office (RIO), with the goal of accelerating new technologies, particularly in sectors like biotech and healthcare, by reducing regulatory barriers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Some two-and-a-half years after buying the Novo Holdings portfolio company ReViral and its respiratory syncytial virus (RSV) candidate sisunatovir in a deal worth up to $525 million, US pharma giant Pfizer may have signalled an early end to the pricey project. 9 October 2024
US pharma major Bristol Myers Squibb’s recent approval from the US Food and Drug Administration (FDA) for Cobenfy (xanomeline and trospium chloride) for the treatment of adults with schizophrenia is a win for the company. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Israel-based Teva Pharmaceutical Industries today announced that the US Food and Drug Administration (FDA) has accepted, and the European Medicines Agency (EMA) has validated, applications for TVB-009P, a biosimilar candidate to Prolia (denosumab). 8 October 2024
UK-based Mestag Therapeutics has entered into a license and collaboration agreement with Merck & Co to explore new therapeutic options for inflammatory diseases. 8 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.